An interventional study of OBE-COACH program and Connected devices in Overweight and Obesity, sponsored by Assistance Publique - Hôpitaux de Paris. Completed at 1 site in France. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-09-30.
Sponsored by Assistance Publique - Hôpitaux de Paris · Not applicable, Interventional, and Supportive care
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 58 studies in Obesity by Assistance Publique - Hôpitaux de Paris — 16 open to participants now, 16 under way, 1 of them phase 3. Obesity · Assistance Publique - Hôpitaux de Paris.
Among the 58 studies in Obesity by Assistance Publique - Hôpitaux de Paris, this one is the 9th largest by enrollment of the 38 interventional ones that give a count, is one of 3 that started in 2024, is one of 30 with no phase, and was the 42nd registered.
11,564 studies on the registry are indexed under Obesity; 2,063 are open to participants now.
Browse Obesity studies →16 of the 58 studies in Obesity by Assistance Publique - Hôpitaux de Paris are open now, in 1 country. Recruiting first, the newest first:
Assistance Publique - Hôpitaux de Paris · Sites in France
Ages 18–85
Assistance Publique - Hôpitaux de Paris · Sites in France
Ages 18–64 · Women only · Healthy volunteers
Assistance Publique - Hôpitaux de Paris · Sites in France
Ages 18+
Assistance Publique - Hôpitaux de Paris · Sites in France
Ages 18+
Assistance Publique - Hôpitaux de Paris · Sites in France
Ages 12+
By country, each count listing its studies:
Of the 1,352 Obesity studies recruiting now, 382 (28%) set no upper age limit and 867 (64%) stop at 75 or younger; 169 take children under 18; 491 take healthy volunteers.
This study: 18 Years to 75 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
58 studies; the count open now beside each. This study's row is marked.
First in 2002; this study’s year is marked. 3 started in 2024.
This study's enrollment of 346 is above the median of 67 across 9,043 interventional studies indexed under Obesity.
Median enrollment 110 across the 38 interventional studies, 175 across the 20 observational. Of the 36 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
Assistance Publique - Hôpitaux de Paris is the lead sponsor of 3,598 studies on the registry; 1,038 are open to participants now.
4 of the studies in Obesity by Assistance Publique - Hôpitaux de Paris that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06867354Assistance Publique - Hôpitaux de ParisPrevalence, Determinants and Consequences of Dyspnea During Weaning in Critically Ill Obese Patients | 2027-03 |
| NCT06380426Assistance Publique - Hôpitaux de ParisA Multicenter Pharmacoepidemiological Cohort on Real Life Use of Semaglutide in Adolescents or Adults With Monogenic Obesity | 2027-04-30 |
| NCT04893954Assistance Publique - Hôpitaux de ParisProspective Study on the Consequences of Weight Loss After Bariatric Surgery on Obese Patients' Spine. | 2027-07 |
| NCT06899997Assistance Publique - Hôpitaux de ParisStudy of the Effects of Time-Restricted Feeding on the Immune Function of Individuals With Obesity | 2027-09-15 |
Add all 4 to your calendar (.ics) → With an account.
Among the 58 studies in Obesity by Assistance Publique - Hôpitaux de Paris, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The OBE-COACH program is an automated online nutritional coaching service that was evaluated in its first version (MXS-CARE program) in a clinical trial coordinated by our team, in type 2 diabetic patients with abdominal obesity. Results have confirmed the efficiency of the program to improve lifestyle habits, including the 4-month diet, and to reduce weight and HbA1c levels.
Based on our experience and the scientific literature, the investigators assume that adherence to the program may diminish in the long term to the point of calling into question its efficiency. So IRIADE compagny developed an enhanced program called OBE-COACH. The OBE-COACH program has been specifically designed to facilitate long-term user adherence. The OBE-COACH program, integrates a bidirectional interactive link between the patient and an automated support system (IRIADE-MED system) associated with an inexpensive remote human support.
In the TOOLBAR study, the investigators will evaluate the efficiency of the OBE-COACH solution in a population of obese patients or overweight persons with at least one cardiometabolic risk factor.
A group of patients will have access to the OBE-COACH program. It will be compared to a control group which will receive an e-learning program with free access to advice sheets via the web, to a menu generator, videos and a catalog of physical activity, (resources made available by the web site www.mangerbouger.fr (public health France, ministry in charge of health) . Indeed, the investigators judged that the loss of patients during follow-up would be greater if e-learning was not offered in the control group.
The management of patients in the TOOLBAR study will be in accordance with French recommendations: a patient who is overweight should benefit from a dietary, physical activity, psychological assistance and medical monitoring advices which can be provided by a general practitioner. In the control group, subjects have access to an e-learning program, including free access via the web to a nutritional information portal and to automated tools providing information and advice for adopting a balanced, low-carb diet and to practice physical activity in line with the guidelines of the national health nutrition plan (PNNS). However, this group will not have access to the OBE-COACH program. The usual follow-up with the attending doctor will be continued.
Patients will be assessed at baseline, 6 months and 12 months. In an ancillary study they could be also assessed at 24 months.
11,564 studies on the registry are indexed under Obesity; 2,063 are open to participants now.
This study's enrollment of 346 is above the median of 67 across 9,043 interventional studies indexed under Obesity.
Browse Obesity studies →Assistance Publique - Hôpitaux de Paris is the lead sponsor of 3,598 studies on the registry; 1,038 are open to participants now.
Compared within Obesity, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Overweight. The counts are of registry records indexed under each term, refreshed daily. How we classify →
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
DSM diagnostic criteria
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The OBE-COACH experimental group: access to the complete OBE-COACH program
Behavioral: OBE-COACH program · Device: Connected devices · Device: Connected Activity Tracer
The control group: access to an e-learning program with free access via the web to advice sheets, a menu generator and a catalog of physical activity (resources made available by the site www.mangerbouger.fr ; Public Health France, Ministry of Health) and provision of connected devices (auto-tensiometer and balance).
Device: Connected devices · Device: Connected Activity Tracer · Behavioral: e-learning program
OBE-COACH works through private exchanges between the user and an automatic generator of recommendations, advice and messages of encouragement. Web focus groups are propoposed by specialist to respond to the questions of the participants and a tele-interview at 6 months with a dietetician to encourage and assist the patient to make the best use of the program. The program is divided into missions to perform. These missions are grouped into 10 families. The completion of each mission and the correct answers to the quiz offer points and bonuses. To promote better adherence to the program, missions are not repetitive. They are proposed to surprise the user and constantly renew his desire to connect to the program and achieve goals. The intensity level of the program is selected by the user at any time.
Connected devices provide to patient are auto-tensiometer and balance. These devices will not be connected to the OBE-COACH program. The auto-tensiometer (Tensio-screen, Terraillon) is a connected tensiometer allowing the patient to measure by himself with an armband his systolic and diastolic blood pressure and his heart rate. The balance (Web coach premium, Terraillon) is a connected scale to collect body weight.
The Activity Tracer (activi-T band, Terraillon) is a a wristband connected activity tracer worn on the wrist that tracks the patient's physical activity and calculates the number of steps, distance traveled and calories burned. The Activity Tracer will not be connected to the OBE-COACH program.
e-learning program with free access via the web to advice sheets, a menu generator and a catalog of physical activity (resources made available by the site www.mangerbouger.fr ; Public Health France, Ministry of Health)
Weight reduction of at least 5% between 0 and 12 months.
Weight reduction of at least 5% between 0 and 12 months. The weight, in Kg, will be measured in a state of fastness ≥ 8h, in participants wearing light clothing without shoes on the same scales calibrated at inclusion and 12 months of follow-up.
Time frame: 12 months
Weight reduction of at least 5% between 0 and 6 months.
Weight, in Kg, measured in the same conditon at baseline and 6 months.
Time frame: 6 months
Weight change between 0 and 6 months
Weight, in Kg, measured in the same conditon at baseline and 6 months.
Time frame: 6 months
Weight change between 0 and 12 months
Weight, in Kg, measured in the same conditon at baseline and 12 months.
Time frame: 12 months
Waist change between 0 and 6 months
Waist, in cm, measured midway between the last ribs and the anterior superior iliac crest
Time frame: 6 months
Waist change between 0 and 12 months
Waist, in cm, measured midway between the last ribs and the anterior superior iliac crest
Time frame: 12 months
Triglycerids change between 0 and 12 months
Plasma fasting levels of triglycerides in g/L
Time frame: 12 months
HDL cholesterol change between 0 and 12 months
Plasma fasting levels of HDL cholesterol in g/L
Time frame: 12 months
LDL cholesterol change between 0 and 12 months
Plasma fasting levels of LDL cholesterol in g/L
Time frame: 12 months
non-HDL cholesterol change between 0 and 12 months
Plasma fasting levels of non-HDL cholesterol in g/L (total cholesterol less HDL-C)
Time frame: 12 months
Blood glucose change between 0 and 12 months
Plasma fasting levels of glucose in g/L
Time frame: 12 months
HbA1c change between 0 and 12 months
Plasma fasting levels of HbA1c in percentage
Time frame: 12 months
Systolic blood pressure change between 0 and 12 months
Systolic blood pressure in mmHg as the average of the last 2 automatic measurements out of 3 taken at the level of one arm and spaced about 2 min in the cabinet or by the patient with the auto-tensiometer
Time frame: 12 months
Diastolic blood pressure change between 0 and 12 months
Diastolic blood pressure in mmHg as the average of the last 2 automatic measurements out of 3 taken at the level of one arm and spaced about 2 min in the cabinet or by the patient with the auto-tensiometer
Time frame: 12 months
Triglycerids change between 0 and 6 months
Plasma fasting levels of triglycerides in g/L
Time frame: 6 months
HDL cholesterol change between 0 and 6 months
Plasma fasting levels of HDL cholesterol in g/L
Time frame: 6 months
LDL cholesterol change between 0 and 6 months
Plasma fasting levels of LDL cholesterol in g/L
Time frame: 6 months
non-HDL cholesterol change between 0 and 6 months
Plasma fasting levels of non-HDL cholesterol in g/L (total cholesterol less HDL-C)
Time frame: 6 months
Blood glucose change between 0 and 6 months
Plasma fasting levels of glucose in g/L
Time frame: 6 months
HbA1c change between 0 and 6 months
Plasma fasting levels of HbA1c in percentage
Time frame: 6 months
Systolic blood pressure change between 0 and 6 months
Systolic blood pressure in mmHg as the average of the last 2 automatic measurements out of 3 taken at the level of one arm and spaced about 2 min in the cabinet or by the patient with the auto-tensiometer
Time frame: 6 months
Diastolic blood pressure change between 0 and 6 months
Diastolic blood pressure in mmHg as the average of the last 2 automatic measurements out of 3 taken at the level of one arm and spaced about 2 min in the cabinet or by the patient with the auto-tensiometer
Time frame: 6 months
Change in adherence to the Mediterranean diet : Score PREDIMED
Change between 0 and 12 months of adherence to mediterranean diet,evaluated by the dietetic score PREDIMED (validated checklist of 14 items). Higher scores indicate greater adherence to the diet assigned
Time frame: 12 months
Change in adherence to the Mediterranean diet : fruits and vegetables consumption
Change between 0 and 12 months in terms of perrcentage of consumption of fruits and vegetables on the recommended 400 g/day
Time frame: 12 months
Change in adherence to the Mediterranean diet : Score PREDIMED
Change between 0 and 6 months of adherence to mediterranean diet,evaluated by the dietetic score PREDIMED (validated checklist of 14 items). Higher scores indicate greater adherence to the diet assigned
Time frame: 6 months
Change in adherence to the Mediterranean diet : fruits and vegetables consumption
Change between 0 and 6 months in terms of percentage of consumption of fruits and vegetables on the recommended 400 g/day
Time frame: 6 months
Change between 0 and 12 months of Energy intake
Energy intake, in Kcal/day, evaluated with the validated NAQA questionnaire
Time frame: 12 months
Change between 0 and 12 months of proteins intake, in g/day, evaluated with the validated NAQA questionnaire
Time frame: 12 months
Change between 0 and 12 months of sucrose intake in g/day, evaluated with the validated NAQA questionnaire
Time frame: 12 months
Change between 0 and 12 months of lipids intake in g/day, evaluated with the validated NAQA questionnaire
Time frame: 12 months
Change between 0 and 12 months of cholesterol intake
Cholesterol intake, in mg/day, evaluated with the validated NAQA questionnaire
Time frame: 12 months
Change between 0 and 12 months of calcium intake in mg/day, evaluated with the validated NAQA questionnaire
Time frame: 12 months
Change between 0 and 12 months of sugary drinks consumption in number of glasses/day
Time frame: 12 months
Change between 0 and 12 months of alcohol drinks consumption in number of glasses/day
Time frame: 12 months
Change between 0 and 6 months of sugary drinks consumption in number of glasses/day
Time frame: 6 months
Change between 0 and 6 months of alcohol drinks consumption in number of glasses/day
Time frame: 6 months
Change between 0 and 12 months of tobacco consumption in number of cigarettes/day
Time frame: 12 months
Change between 0 and 6 months of tobacco consumption in number of cigarettes/day
Time frame: 6 months
Change between 0 and 12 months of Adherence to the WHO recommendations for physical activity, measured in Metabolic Equivalent of Task, MET, evaluated with the GPAQ questionnaire.
Time frame: 12 months
Change between 0 and 6 months of Adherence to the WHO recommendations for physical activity, measured in Metabolic Equivalent of Task, MET, evaluated with the GPAQ questionnaire.
Time frame: 6 months
Adherence to OBE-COACH program at 12 months, evaluated by the average percentage of questions (sent by IRIADE) with replies from the subject per week during the previous month.
Time frame: 12 months
Adherence to OBE-COACH program at 12 months, evaluated by the number of participation in web focus groups over the last 6 months.
Time frame: 12 months
Adherence to OBE-COACH program at 6 months, evaluated by the average percentage of questions (sent by IRIADE) with replies from the subject per week during the previous month.
Time frame: 6 months
Adherence to OBE-COACH program at 6 months, evaluated by the number of participation in web focus groups over the last 6 months.
Time frame: 6 months
Change between 0 and 12 months of Food impulsivity evaluated by the TFEQ21 questionnaire
Time frame: 12 months
Change between 0 and 6 months of Food impulsivity evaluated by the TFEQ21 questionnaire
Time frame: 6 months
Evolution between 0 and 12 months of Symptoms of anxiety, measured with the HAD questionnaire (score 0 to 21)
Time frame: 12 months
Plan to share: Yes — Data are available upon reasonable request. The procedures carried out with the French data privacy authority (CNIL, Commission nationale de l'informatique et des libertés) do not provide for the transmission of the database, nor do the information and consent documents signed by the patients. Consultation by the editorial board or interested researchers of individual participant data that underlie the results reported in the article after deidentification may nevertheless be considered, subject to prior determination of the terms and conditions of such consultation and in respect for compliance with the applicable regulations.
Supporting information: Study protocol, Statistical analysis plan, Informed consent form
Time frame: Beginning 3 months and ending 3 years following article publication. Requests out of these time frame can also be submitted to the sponsor
Access criteria: Researchers who provide a methodologically sound proposal
No publications or documents are linked to this record.
Ran from Jan 2024 to primary completion in Jun 2025, 17 months.
Of 3,697 non-industry interventional studies with no phase under Obesity, half reached primary completion within 23 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 43. This study's 17 months is below that.
Counting every sponsor, half of 3,861 studies reached it within 22 months; a quarter within 9 and three quarters within 42.
Since we started tracking on Sep 25, 2026, the dates moved once, on Sep 30, 2026: primary completion Nov 2025 → Jun 2025 and completion Nov 2026 → Jun 2025.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is completed, as verified in May 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Assistance Publique - Hôpitaux de Paris →